Occlutech is a leading specialist provider of minimally invasive cardiac devices, with a mission to improve the quality of life for people with heart conditions. The vision is to become a global leading specialist provider in cardiac devices, addressing congenital heart defects, stroke prevention and heart failure.
Since 2003, Occlutech has developed, manufactured, and commercialized occluders and interatrial shunt products. Occlutech has a broad and proven portfolio, based on proprietary technology, and over 200 patents with more than 139,000 products sold.
Occlutech markets and sells its structural heart and interatrial shunt products to hospitals and clinics in approximately 85 countries through its direct sales organization and international network of distribution partners.
Occlutech has around 275 employees and maintains manufacturing and R&D facilities in Jena, Germany and Istanbul, Turkey, with a global supply and customer support hub located in Helsingborg, Sweden.
Since 2003, Occlutech has developed, manufactured, and commercialized occluders and interatrial shunt products. Occlutech has a broad and proven portfolio, based on proprietary technology, and over 200 patents with more than 139,000 products sold.
Occlutech markets and sells its structural heart and interatrial shunt products to hospitals and clinics in approximately 85 countries through its direct sales organization and international network of distribution partners.
Occlutech has around 275 employees and maintains manufacturing and R&D facilities in Jena, Germany and Istanbul, Turkey, with a global supply and customer support hub located in Helsingborg, Sweden.
Location: Switzerland
Employees: 51-200
Total raised: $21.62M
Founded date: 2003
Investors 1
| Date | Name | Website |
| - | Centripeta... | centripeta... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.08.2011 | - | $21.62M | - |
Mentions in press and media 18
| Date | Title | Description |
| 09.03.2026 | Occlutech to gain Alkem as majority shareholder | Founded in 2003, Occlutech develops, manufactures and commercialises minimally invasive cardiac devices for congenital heart defects, stroke prevention and heart failure. Headquartered in Switzerland, the company sells its products in more... |
| 05.04.2023 | Occlutech Receives Subscription Commitment of Bonds Amounting to EUR 40 million in Nominal Value Under a Total Frame of EUR 75 million to Finance US Expansion and Growth | - |
| 01.02.2023 | Occlutech Announces Change to the Executive Management Team | SCHAFFHAUSEN, SWITZERLAND / ACCESSWIRE / February 1, 2023 / Occlutech Holding AG Occlutech Holding AG ("Occlutech"), one of the world's leading providers of minimally invasive structural heart disease devices, appoints Dr. Morwan ... |
| 24.11.2022 | Occlutech Q3 2022 – Revenue Growth, Increased Market Activity and Operational Preparations | SCHAFFHAUSEN, CH / ACCESSWIRE / November 24, 2022 / Occlutech Holding AG Occlutech Holding AG (Occlutech) is a leading specialist provider of minimally invasive structural heart implants. The company sells and markets its products in around... |
| 24.08.2022 | Occlutech Q2 2022 - Positive Revenue Growth and Important Milestones Achieved in the Strategic US Market | SCHAFFHAUSEN, CH / ACCESSWIRE / August 24, 2022 / Occlutech Holding AG Occlutech Holding AG (Occlutech) is a leading specialist provider of minimally invasive structural heart implants. The company sells and markets its products in around 8... |
| 19.05.2022 | Occlutech Signs Exclusive US Distribution Agreement with B. Braun Interventional Systems Inc., an Affiliate of B. Braun Medical Inc. | SCHAFFHAUSEN, CH / ACCESSWIRE / May 19, 2022 / Occlutech Holding AG Occlutech Holding AG (Occlutech), a leading specialist provider of minimally invasive structural heart implants, has signed an exclusive distribution agreement with B. Brau... |
| 16.08.2021 | Occlutech granted important conditional FDA approval for PFO Study (OCCLUFLEX) in the U.S. USA - English USA - English | |
| 16.08.2021 | Occlutech granted important conditional FDA approval for PFO Study (OCCLUFLEX) in the U.S. | SCHAFFHAUSEN, Switzerland, Aug. 16, 2021 /PRNewswire/ -- Occlutech Holding AG ("Occlutech"), one of the world´s leading providers of minimally invasive structural heart disease devices, announces the conditional U.S. Food and Drug... |
| 01.06.2021 | Occlutech takes important step towards approval in China | |
| 01.06.2021 | Occlutech takes important step towards approval in China | SCHAFFHAUSEN, Switzerland, June 1, 2021 /PRNewswire/ -- Occlutech AG ("Occlutech" or the "Company") today announces that the planned recruitment of 180 patients has been reached in the Company's trial in China for its AS... |
Show more